Coalition report demonstrates sub-five percent trial enrollment in global cancer populations, highlighting a hub-and-spoke network to expand access.
Summary: Despite exponentially increased industry investment in oncology research and development with more than $80 billion spent annually, patient enrollment in clinical trials remains below 5% globally. Our multistakeholder international cancer coalition envisions ecosystem transformation with capacity building through a global “hub-and-spoke” network model to expand access to and accelerate clinical trials, thus ending cancer as a major cause of death in this lifetime.
No takes yet. Share an insight, caveat, or question.
Adewole et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: